Yan Song
Education
Ph.D., epidemiology, University of California, Los Angeles; M.S., epidemiology and biostatistics, and M.B.B.S., medicine, Peking University
Summary of Experience
Dr. Song is an epidemiologist with expertise in biostatistics and clinical medicine, which he uses to address a wide array of analytical questions in health care. He has broad experience designing and implementing advanced and innovative real-world data analytic and economic modeling solutions for pharmaceutical clients. Dr. Song conducts research to evaluate and compare the clinical, economic, and humanistic impacts of diseases and treatments across a variety of therapeutic areas. He is experienced in disease areas such as oncology, hematology, infectious diseases and vaccines, dermatology, rheumatology, cardiology, and endocrinology. Dr. Song has provided cross-indication consulting for multiple blockbuster pharmaceutical products, as well as novel pipeline agents. In his work, he uses data from clinical trials, administrative claims, medical chart reviews, surveys, qualitative interviews, and medical literature. His research has covered many different study types, including disease epidemiology, burden of illness, disease treatment and management patterns, comparative effectiveness research, individualized medicine, systematic literature reviews, indirect treatment comparisons, economic modeling such as cost-effectiveness analyses and budget impact analyses, analyses of patient-reported outcomes, and preference research such as discrete choice experiments. Dr. Song’s work has been published in peer-reviewed journals and presented at international conferences on medical and health care research.
-
Projected Impact of Omidubicel-onlv on Racial/Ethnic Disparities in Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) Outcomes in Hematologic Malignancies
Advances in Therapy, Vol. 41 (2024), pp. 1637–1651
2024Khera N, Edwards ML, Song Y, Sun R, Manghani R, Shin H, Simantov R, Signorovitch J, Sivaraman S, Gergis U
-
Real-World Neoadjuvant Treatment Patterns and Outcomes in Resected Non-Small-Cell Lung Cancer
Clinical Lung Cancer, 2024
2024Donington J, Hu X, Zhang S, Song Y, Arunachalam A, Chirovsky D, Gao C, Lerner A, Jiang A, Signorovitch J, Samkari A
-
Treatment patterns of patients with worsening heart failure with reduced ejection fraction
ESC Heart Failure, 2024
2024Greene SJ, Gaggin HK, Zhou M, Bash LD, Lautsch D, Djatche L, Song Y, Signorovitch J, Stevenson AS, Blaustein RO, Butler J
-
Epidemiology and economic burden of Von Hippel-Lindau Disease-associated central nervous system hemangioblastomas and pancreatic neuroendocrine tumors in the United States
Orphanet Journal of Rare Diseases, 2024
2024Jonasch E, Song Y, Freimark J, Berman R, Nguyen H, Signorovitch J, Sundaram M
-
Incidence of pneumococcal disease in children ≤48 months old in the United States: 1998–2019
Vaccine, 2024
2024Mohanty S, Done N, Liu Q, Song Y, Wang T, Gaburo K, Sarpong EM, White M, Weaver JP, Signorovitch J, Weiss T
-
Contemporary outpatient management of patients with worsening heart failure with reduced ejection fraction: Clinical outcome results from the CHART-HF study
International Journal of Cardiology: Cardiovascular Risk and Prevention, 2024
2024Gaggin HK, Greene SJ, Zhou M, Lautsch D, Bash LD, Djatche L, Song Y, Signorovitch J, Stevenson AS, Blaustein RO, Butler J
-
Real-world anti-seizure treatment and adverse events among individuals living with drug-resistant focal epilepsy in the United States
Epilepsia Open, 2024
2024Mao J, Takahashi K, Cheng M, Xu C, Boca A, Song Y, Dandurand A
-
Seizure burden and healthcare resource utilization among people living with drug-resistant focal epilepsy in the United States
Current Medical Research and Opinion, 2024
2024Mao J, Song Y, Cheng M, Xu C, Boca A, Dandurand A, Takahashi K
-
Disease-Free Survival as a Predictor of Overall Survival in Localized Renal Cell Carcinoma Following Initial Nephrectomy: A Retrospective Analysis of Surveillance, Epidemiology and End Results-Medicare Data
International Journal of Urology, 2023
2023Haas NB, Song Y, Rogerio JW, Zhang S, Carley C, Zhu J, Bhattacharya R, Signorovitch J, Sundaram M
-
Economic Burden of Acute Otitis Media, Pneumonia, and Invasive Pneumococcal Disease in Children in the United States after the Introduction of 13-Valent Pneumococcal Conjugate Vaccines During 2014-2018
BMC Health Services Research, 2023
2023Hu T, Song Y, Done N, Mohanty S, Liu Q, Sarpong EM, Lemus-Wirtz E, Signorovitch J, Weiss T
-
Epidemiology and Economic Burden of Von Hippel-Lindau Disease-Associated Renal Cell Carcinoma in the United States
Clinical Genitourinary Cancer, 2023
2023Jonasch E, Song Y, Freimark J, Berman R, Nguyen H, Signorovitch J, Sundaram M
-
Incidence of Non-Invasive All-Cause Pneumonia in Children in the United States before and after the Introduction of Pneumococcal Conjugate Vaccines: A Retrospective Claims Database Analysis
Pneumonia, 2023
2023Hu T, Sarpong EM, Song Y, Done N, Liu Q, Lemus-Wirtz E, Signorovitch J, Mohanty S, Weiss T
-
Prevalence of Potential Drug-Drug Interactions with Ritonavir-Containing Covid-19 Therapy
Journal of Managed Care & Specialty Pharmacy, 2023
2023Igho-Osagie E, Puenpatom A, Williams MG, Song Y, Yi D, Wang J, Berman R, Gu M, He C
-
Evaluation of Disease-Free Survival as a Predictor of Overall Survival and Assessment of Real-World Burden of Disease Recurrence in Resected Early-Stage Non-Small Cell Lung Cancer
Journal of Managed Care & Specialty Pharmacy, 2023
2023West H, Hu X, Zhang S, Song Y, Chirovsky D, Gao C, Lerner A, Jiang A, Signorovitch J, Samkari A
-
Treatment Patterns and Outcomes in Resected Early-Stage Non-Small Cell Lung Cancer: An Analysis of the Seer-Medicare Data
Clinical Lung Cancer, 2023
2023West H, Hu X, Zhang S, Song Y, Chirovsky D, Gao C, Lerner A, Jiang A, Signorovitch J, Samkari A
-
Treatment Patterns and Healthcare Resource Use in Medicare Beneficiaries with Parkinson's Disease
ClinicoEconomics and Outcomes Research, 2023
2023 -
Patient and Physician Preferences for Acute Myeloid Leukemia Maintenance Treatments Following Hematopoietic Stem Cell Transplantation
Patient preference and adherence, 2023
2023Saini L, Griffin JD, Pandya BJ, Shah MV, Zhou M, Yang H, Song Y, Marshall DA
-
Healthcare costs among patients with hematologic malignancies receiving allogeneic transplants: a US payer perspective
Blood Advances, 2023
2023Maziarz RT, Gergis U, Edwards ML, Song Y, Liu Q, Anderson A, Signorovitch JE, Manghani R, Simantov R, Shin H, Sivaraman S
-
Event-Free Survival as a Predictor of Overall Survival and Recurrence Burden of Patients with Non-Small Cell Lung Cancer Receiving Neoadjuvant Therapy
The Journal of Thoracic and Cardiovascular Surgery, 2023
2023Donington J, Hu X, Zhang S, Song Y, Arunachalam A, Chirovsky D, Gao C, Lerner A, Jiang A, Signorovitch J, Samkari A
-
Real-world treatment patterns and effectiveness of cladribine tablets in patients with relapsing forms of multiple sclerosis in the United States
Multiple Sclerosis and Related Disorders, 2023
2023 -
Patient-reported outcomes of upadacitinib versus abatacept in patients with rheumatoid arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 12- and 24-week results of a phase 3 trial
Arthritis Research & Therapy, 2022
2022Bergman M, Tundia N, Martin N, Suboticki JL, Patel J, Goldschmidt D, Song Y, Wright GC
-
Cost-effectiveness analysis of semaglutide 2.4 mg for the treatment of adult patients with overweight and obesity in the United States
Journal of Managed Care & Specialty Pharmacy, 2022
2022Kim N, Wang J, Burudpakdee C, Song Y, Ramasamy A, Xie Y, Sun R, Kumar N, Wu EQ, Sullivan SD
-
Health-Related Quality of Life Following Allogeneic Hematopoietic Cell Transplantation with Omidubicel versus Umbilical Cord Blood
Transplantation and Cellular Therapy, 2022
2022Lin C, Sajeev G, Stiff PJ, Brunstein CG, Cutler C, Sanz G, Lindemans CA, Rezvani AR, Hanna R, Koh LP, Maziarz RT, Hwang WYK, Song Y, Liu Q, Manghani R, Sivaraman S, Signorovitch J, Horwitz ME, Sung AD
-
Clinical and economic burdens of recurrence following nephrectomy for intermediate high- or high-risk renal cell carcinoma: A retrospective analysis of Surveillance, Epidemiology, and End Results-Medicare data
Journal of Managed Care & Specialty Pharmacy, 2022
2022Sundaram M, Song Y, Rogerio JW, Zhang S, Bhattacharya R, Adejoro O, Carley C, Zhu J, Signorovitch J, Haas NB
-
Incidence of invasive pneumococcal disease in children with commercial insurance or Medicaid coverage in the United States before and after the introduction of 7- and 13-valent pneumococcal conjugate vaccines during 1998-2018
BMC Public Health, 2022
2022Hu T, Song Y, Done N, Liu Q, Sarpong EM, Lemus-Wirtz E, Signorovitch J, Mohanty S, Weiss T
-
Contemporary Outpatient Management of Patients with Worsening Heart Failure with Reduced Ejection Fraction: Rationale and Design of the CHART-HF Study
American Heart Journal, 2022
2022Greene SJ, Lautsch D, Gaggin HK, Djatche LM, Zhou M, Song Y, Signorovitch J, Stevenson AS, Blaustein RO, Butler J
-
Matching-adjusted Indirect Comparison of the Efficacy of Loncastuximab Tesirine Versus Treatment in the Chemoimmunotherapy Era for Relapsed/Refractory Diffuse Large B-cell Lymphoma
Clinical Lymphoma, Myeloma & Leukemia, 2022
2022Hamadani M, Chen L, Song Y, Xu MK, Liao L, Caimi PF, Carlo-Stella C
-
The Economic Burden of Recurrence in Triple-Negative Breast Cancer Among Working Age Patients in the United States
Advances in Therapy, 2022
2022Sieluk J, Song Y, Freimark J, Huang M, Haiderali A, Berman R, Wang T, Signorovitch J, Hirshfield KM
-
Incidence of acute otitis media in children in the United States before and after the introduction of 7- and 13-valent pneumococcal conjugate vaccines during 1998-2018
BMS Infectious Diseases, 2022
2022Hu T, Done N, Petigara T, Mohanty S, Song Y, Liu Q, Lemus-Wirtz E, Signorovitch J, Sarpong E, Weiss T
-
Upadacitinib improves patient-reported outcomes vs placebo or adalimumab in patients with rheumatoid arthritis: results from SELECT-COMPARE
Rheumatology, 2021
2021Strand V, Tundia N, Bergman M, Ostor A, Durez P, Song IH, Enejosa J, Schlacher C, Song Y, Roy Fleischmann 7
-
Post-transplant maintenance therapy in patients with FLT3-mutated acute myeloid leukemia: Real-world treatment patterns and outcomes
European Journal of Haematology, 2021
2021Griffin JD, Song Y, Yang H, Freimark J, Shah MV
-
Comparative Efficacy of JAK Inhibitors for Moderate-To-Severe Rheumatoid Arthritis: A Network Meta-Analysis
Advances in Therapy
2020Pope J, Sawant R, Tundia N, Du EX, Qi CZ, Song Y, Tang P, Betts KA
-
An Economic Evaluation of Pembrolizumab Versus Other Adjuvant Treatment Strategies for Resected High-Risk Stage III Melanoma in the USA
Clinical Drug Investigation, 2020
2020Bensimon AG, Zhou ZY, Jenkins M, Song Y, Gao W, Signorovitch J, Krepler C, Scherrer E, Wang J, Aguiar-Ibáñez R
-
Cost-effectiveness of pembrolizumab with axitinib as first-line treatment for advanced renal cell carcinoma
Current Medical Research and Opinion, 2020
2020Bensimon AG, Zhong Y, Swami U, Briggs A, Young J, Feng Y, Song Y, Signorovitch J, Adejoro O, Chakravarty A, Chen M, Perini RF, Geynisman DM
-
Adverse Events Associated with Cumulative Corticosteroid Use in Patients with Castration-Resistant Prostate Cancer: An Administrative Claims Analysis
Drug Safety, 2020
2020Schultz NM, Penson DF, Wilson S, Song Y, Yang H, Ramaswamy K, Lowentritt B
-
Clinical and Economic Burden of Patients with Chronic Hepatitis C with Versus Without Antiviral Treatment in Japan: An Observational Cohort Study Using Hospital Claims Data
Infectious Diseases and Therapy, 2019
2019Yamazaki K, Macaulay D, Song Y, Gonzalez YS
-
Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs
Arthritis Research & Therapy, 2019
2019Strand V, Schiff M, Tundia N, Friedman A, Meerwein S, Pangan A, Ganguli A, Fuldeore M, Song Y, Pope J
-
Economic Burden of Switching to Different Biologic Therapies Among Tumor Necrosis Factor Inhibitor-Experienced Patients with Psoriatic Arthritis
Rheumatology and Therapy, 2019
2019 -
Health Care Resource Utilization and Costs Associated with Corticosteroid Use in Patients with Castration-Resistant Prostate Cancer: An Administrative Claims Analysis
Journal of Managed Care & Specialty Pharmacy, 2019
2019Schultz NM, Penson DF, Wilson SD, Song Y, Yang H, Ramaswamy K, Lowentritt B
-
Cost-effectiveness of pembrolizumab for the adjuvant treatment of resected high-risk stage III melanoma in the United States
Journal of Medical Economics, 2019
2019Bensimon AG, Zhou ZY, Jenkins M, Song Y, Gao W, Signorovitch J, Krepler C, Liu FX, Wang J, Aguiar-Ibáñez R
-
Economic burden of patients with inadequate response to targeted immunomodulators for rheumatoid arthritis
Journal of Managed Care and Specialty Pharmacy. 01 Apr 2018;24(4):344-352
2018Strand V, Tundia N, Song Y, Macaulay D, Fuldeore M
-
Incidence of catheter-related complications among Japanese patients with central venous catheters as well as patients with short bowel syndrome
Clinical and Experimental Gastroenterology. 2018 Nov 28;11:439-445
2018Wing VK, Song Y, Xiang C, Liu X, Macaulay D, Ponsillo M, Blumentals WA
-
Treatment Duration, Healthcare Resource Utilization, and Costs Among Chemotherapy-Naive Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate: A Retrospective Claims Analysis
Advances in Therapy. 2018 Oct;35(10):1639-1655
2018Schultz NM, Flanders SC, Wilson S, Brown BA, Song Y, Yang H, Lechpammer S, Kassabian V
-
Treatment Patterns and Healthcare Resource Utilization in Patients with FLT3-Mutated and Wild Type Acute Myeloid Leukemia: A Medical Chart Study
European Journal of Haematology. December 22, 2018
2018 -
Health-related quality of life and work productivity associated with HiSCR and NRS30 response among patients with moderate to severe hidradenitis suppurativa
Journal of the American Academy of Dermatology, June 2017, Volume 76, Issue 6
2017 -
Benefit-risk trade-offs for treatment decisions in moderate-to-severe rheumatoid arthritis: focus on the patient perspective
Rheumatology International. Jun 16 2017:1-12
2017 -
Number needed to treat and associated incremental costs of treatment with enzalutamide versus abiraterone acetate plus prednisone in chemotherapy-naive patients with metastatic castration-resistant pr
Journal of Medical Economics. Feb 2017;20(2):121-128
2017Massoudi M, Balk M, Yang H, Bui CN, Pandya BJ, Guo J, Song Y, Wu EQ, Brown B, Barlev A, Flanders S
-
Network Meta-Analysis and Cost Per Responder of Tumor Necrosis Factor-alpha and Interleukin Inhibitors in the Treatment of Active Ankylosing Spondylitis
Rheumatology and Therapy, 2016 07: 1-14
2016Betts KA, Griffith J, Song Y, Mittal M, Joshi A, Wu EQ, Ganguli A.
-
Number needed to treat and associated incremental costs of treatment with enzalutamide versus abiraterone acetate plus prednisone in chemotherapy-naïve patients with metastatic castration-resistant pr
Journal of Medical Economics, 2016 09: 1-8
2016Massoudi M, Balk M, Yang H, Bui CN, Pandya BJ, Guo J, Song Y, Wu EQ, Brown B, Barlev A, Flanders S.
-
June 6, 2024
-
April 25, 2024
-
April 11, 2024
-
February 26, 2024
-
March 2, 2023
-
February 13, 2023
-
December 7, 2022
-
December 10, 2021
-
October 15, 2021
-
June 4, 2021